Literature DB >> 29146594

Heterologous phosphorylation-induced formation of a stability lock permits regulation of inactive receptors by β-arrestins.

András D Tóth1, Susanne Prokop1, Pál Gyombolai1,2, Péter Várnai1,2, András Balla1,2, Vsevolod V Gurevich3, László Hunyady4,2, Gábor Turu1,2.   

Abstract

β-Arrestins are key regulators and signal transducers of G protein-coupled receptors (GPCRs). The interaction between receptors and β-arrestins is generally believed to require both receptor activity and phosphorylation by GPCR kinases. In this study, we investigated whether β-arrestins are able to bind second messenger kinase-phosphorylated, but inactive receptors as well. Because heterologous phosphorylation is a common phenomenon among GPCRs, this mode of β-arrestin activation may represent a novel mechanism of signal transduction and receptor cross-talk. Here we demonstrate that activation of protein kinase C (PKC) by phorbol myristate acetate, Gq/11-coupled GPCR, or epidermal growth factor receptor stimulation promotes β-arrestin2 recruitment to unliganded AT1 angiotensin receptor (AT1R). We found that this interaction depends on the stability lock, a structure responsible for the sustained binding between GPCRs and β-arrestins, formed by phosphorylated serine-threonine clusters in the receptor's C terminus and two conserved phosphate-binding lysines in the β-arrestin2 N-domain. Using improved FlAsH-based serine-threonine clusters β-arrestin2 conformational biosensors, we also show that the stability lock not only stabilizes the receptor-β-arrestin interaction, but also governs the structural rearrangements within β-arrestins. Furthermore, we found that β-arrestin2 binds to PKC-phosphorylated AT1R in a distinct active conformation, which triggers MAPK recruitment and receptor internalization. Our results provide new insights into the activation of β-arrestins and reveal their novel role in receptor cross-talk.
© 2018 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  G protein-coupled receptor (GPCR); angiotensin II; arrestin; bioluminescence resonance energy transfer (BRET); mitogen-activated protein kinase (MAPK); protein kinase C (PKC); receptor endocytosis

Mesh:

Substances:

Year:  2017        PMID: 29146594      PMCID: PMC5777260          DOI: 10.1074/jbc.M117.813139

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  77 in total

1.  Mutations in arrestin-3 differentially affect binding to neuropeptide Y receptor subtypes.

Authors:  Luis E Gimenez; Stefanie Babilon; Lizzy Wanka; Annette G Beck-Sickinger; Vsevolod V Gurevich
Journal:  Cell Signal       Date:  2014-03-29       Impact factor: 4.315

Review 2.  How many drug targets are there?

Authors:  John P Overington; Bissan Al-Lazikani; Andrew L Hopkins
Journal:  Nat Rev Drug Discov       Date:  2006-12       Impact factor: 84.694

3.  Phosphorylation of the type 1A angiotensin II receptor by G protein-coupled receptor kinases and protein kinase C.

Authors:  M Oppermann; N J Freedman; R W Alexander; R J Lefkowitz
Journal:  J Biol Chem       Date:  1996-05-31       Impact factor: 5.157

4.  Differential β-arrestin2 requirements for constitutive and agonist-induced internalization of the CB1 cannabinoid receptor.

Authors:  Pál Gyombolai; Eszter Boros; László Hunyady; Gábor Turu
Journal:  Mol Cell Endocrinol       Date:  2013-03-27       Impact factor: 4.102

5.  Heterologous activation of protein kinase C stimulates phosphorylation of delta-opioid receptor at serine 344, resulting in beta-arrestin- and clathrin-mediated receptor internalization.

Authors:  B Xiang; G H Yu; J Guo; L Chen; W Hu; G Pei; L Ma
Journal:  J Biol Chem       Date:  2000-11-20       Impact factor: 5.157

6.  Receptor-specific ubiquitination of beta-arrestin directs assembly and targeting of seven-transmembrane receptor signalosomes.

Authors:  Sudha K Shenoy; Robert J Lefkowitz
Journal:  J Biol Chem       Date:  2005-02-07       Impact factor: 5.157

7.  Receptor sequestration in response to β-arrestin-2 phosphorylation by ERK1/2 governs steady-state levels of GPCR cell-surface expression.

Authors:  Justine S Paradis; Stevenson Ly; Élodie Blondel-Tepaz; Jacob A Galan; Alexandre Beautrait; Mark G H Scott; Hervé Enslen; Stefano Marullo; Philippe P Roux; Michel Bouvier
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-31       Impact factor: 11.205

8.  Identification and profiling of novel α1A-adrenoceptor-CXC chemokine receptor 2 heteromer.

Authors:  Sanam Mustafa; Heng B See; Ruth M Seeber; Stephen P Armstrong; Carl W White; Sabatino Ventura; Mohammed Akli Ayoub; Kevin D G Pfleger
Journal:  J Biol Chem       Date:  2012-02-27       Impact factor: 5.157

9.  Visualization of arrestin recruitment by a G-protein-coupled receptor.

Authors:  Arun K Shukla; Gerwin H Westfield; Kunhong Xiao; Rosana I Reis; Li-Yin Huang; Prachi Tripathi-Shukla; Jiang Qian; Sheng Li; Adi Blanc; Austin N Oleskie; Anne M Dosey; Min Su; Cui-Rong Liang; Ling-Ling Gu; Jin-Ming Shan; Xin Chen; Rachel Hanna; Minjung Choi; Xiao Jie Yao; Bjoern U Klink; Alem W Kahsai; Sachdev S Sidhu; Shohei Koide; Pawel A Penczek; Anthony A Kossiakoff; Virgil L Woods; Brian K Kobilka; Georgios Skiniotis; Robert J Lefkowitz
Journal:  Nature       Date:  2014-06-22       Impact factor: 49.962

10.  Engineered hyperphosphorylation of the β2-adrenoceptor prolongs arrestin-3 binding and induces arrestin internalization.

Authors:  Diana Zindel; Adrian J Butcher; Suleiman Al-Sabah; Peter Lanzerstorfer; Julian Weghuber; Andrew B Tobin; Moritz Bünemann; Cornelius Krasel
Journal:  Mol Pharmacol       Date:  2014-11-25       Impact factor: 4.436

View more
  13 in total

Review 1.  GPCRs and Signal Transducers: Interaction Stoichiometry.

Authors:  Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  Trends Pharmacol Sci       Date:  2018-05-05       Impact factor: 14.819

Review 2.  β2 Adrenergic Receptor Complexes with the L-Type Ca2+ Channel CaV1.2 and AMPA-Type Glutamate Receptors: Paradigms for Pharmacological Targeting of Protein Interactions.

Authors:  Kwun Nok Mimi Man; Manuel F Navedo; Mary C Horne; Johannes W Hell
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-09-27       Impact factor: 13.820

Review 3.  Arrestins: Introducing Signaling Bias Into Multifunctional Proteins.

Authors:  Vsevolod V Gurevich; Qiuyan Chen; Eugenia V Gurevich
Journal:  Prog Mol Biol Transl Sci       Date:  2018-09-06       Impact factor: 3.622

Review 4.  Protein kinase sensors: an overview of new designs for visualizing kinase dynamics in single plant cells.

Authors:  Li Zhang; Yohei Takahashi; Julian I Schroeder
Journal:  Plant Physiol       Date:  2021-10-05       Impact factor: 8.005

Review 5.  Aldosterone breakthrough from a pharmacological perspective.

Authors:  Masaki Mogi
Journal:  Hypertens Res       Date:  2022-04-14       Impact factor: 5.528

Review 6.  Biased GPCR signaling: Possible mechanisms and inherent limitations.

Authors:  Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  Pharmacol Ther       Date:  2020-03-19       Impact factor: 12.310

7.  β-arrestin 2 negatively regulates NOD2 signalling pathway through association with TRAF6 in microglia after cerebral ischaemia/reperfusion injury.

Authors:  Lin Chen; Lingjun Kong; Xinbing Wei; Yimeng Wang; Bing Wang; Xiumei Zhang; Jinpeng Sun; Huiqing Liu
Journal:  J Cell Mol Med       Date:  2019-02-22       Impact factor: 5.310

Review 8.  The Role of β-Arrestin Proteins in Organization of Signaling and Regulation of the AT1 Angiotensin Receptor.

Authors:  Gábor Turu; András Balla; László Hunyady
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-06       Impact factor: 5.555

Review 9.  Receptor-Arrestin Interactions: The GPCR Perspective.

Authors:  Mohammad Seyedabadi; Mehdi Gharghabi; Eugenia V Gurevich; Vsevolod V Gurevich
Journal:  Biomolecules       Date:  2021-02-04

10.  Heterotrimeric Gq proteins act as a switch for GRK5/6 selectivity underlying β-arrestin transducer bias.

Authors:  Kouki Kawakami; Masataka Yanagawa; Suzune Hiratsuka; Misaki Yoshida; Yuki Ono; Michio Hiroshima; Masahiro Ueda; Junken Aoki; Yasushi Sako; Asuka Inoue
Journal:  Nat Commun       Date:  2022-01-25       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.